Stocks
Merck Stock Sees 2 Percent Gain After Japan Approves Key Cancer Treatment
Merck stock closed at $151.81 on September 22, 2026, after gaining 1.97 percent from the prior close.
The shares outperformed the S&P 500, which rose 1.49 percent to 7,764.70 during the same session.
This comes following Japan's approval of KEYTRUDA QLEX, a subcutaneous version of Merck's cancer treatment.
Additionally, Merck received a U.S. label update for WINREVAIR after FDA approval based on the Phase 3 HYPERION trial.